Candidaemia in Sweden: A nationwide prospective observational survey

Clinical Microbiology and Infection

Volumn 19, Issue 4, 2013, Pages

  Ericsson, J ^a   Chryssanthou, E ^b   Klingspor, L ^b   Johansson, A G ^c   Ljungman, P ^b   Svensson, E ^d,f   Sjolin J ^e  

^a Västmanland Regional Hospital   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e UPPSALA UNIVERSITY   (Sweden)

^f STATENS SERUM INSTITUT   (Denmark)

Author keywords

Antifungal susceptibility; Candida; Candidaemia epidemiology; Incidence

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE; VORICONAZOLE;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDEMIA; CHILD; FEMALE; FUNGAL STRAIN; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; OBSERVATIONAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; SWEDEN;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; ISSATCHENKIA ORIENTALIS;

EID: 84875536916     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12111     Document Type: Article

References (20)

1. Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003; 37: 634-643.
2. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsch TJ, Feutner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005; 41: 1232-1239.
3. Asmundsdottir LR, Erlandsdottir H, Gottfredsson M. Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland. J Clin Microbiol 2002; 40: 3489-3492.
4. Sandven P, Bevanger L, Digranes A, Haukland H, Mannsåker T, Gaustad P; and the Norwegian yeast study group. Candidemia in Norway (1991-2003): results from a nationwide study. J Clin Microbiol 2006; 44: 1977-1981.
5. Pfaller MA, Diekema DJ; for the International Fungal Surveillance group. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect 2004; 10 (suppl 1): 11-23.
6. Samra Z, Bishara J, Ashkenazi Z et al. Changing distribution of Candida species isolated from sterile and nonsterile sites in Israel. Eur J Clin Microbiol Infect Dis 2002; 21: 542-545.
7. Das I, Nightingale P, Patel M, Jumaa P. Epidemiology, clinical characteristic, and outcome of candidemia: experience in a tertiary care hospital in the UK. Int J Infect Dis 2011; 15: 759-763.
8. Bassetti M, Taramasso L, Nicco E, Molinari M, Mussap M, Viscoli C. Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. PLoS ONE 2011; 6: e24198.
9. Poikonen E, Lyytikäinen O, Anttila VJ et al. Secular trend in candidemia and the use of fluconazole in Finland, 2004-2007. BMC Infect Dis 2010; 10: 312.
10. Axner-Elings M, Botero-Kleiven S, Jensen RH, Arendrup MC. Echinocandin susceptibility testing of Candida isolates collected during a 1-year period in Sweden. J Clin Microbiol 2011; 49: 2516-2521.
11. Amphotericin B rationale for the European Committee on Antimicrobial Susceptibility Testing, EUCAST, clinical breakpoints, version 1.0. 19 November 2010. http://eucast.org.
12. Fluconazole rationale for the EUCAST clinical breakpoints, version 1.0. 5 April 2007. http://eucast.org.
13. Voriconazole rationale for the EUCAST clinical breakpoints version 1.0. 27 August 2008. http://eucast.org.
14. Pfaller MA, Diekema DJ, Andes D et al. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat 2011; 14: 164-176.
15. Arendrup MC, Bruun B, Christensen JJ et al. National surveillance of fungemia in Denmark (2004 to 2009). J Clin Microbiol 2011; 49: 325-334.
16. Falagas ME, Roussos N, Vardakas KZ. Relative frequency of albicans and the various non-albicans Candida spp. among candidemia isolates from inpatients in various parts of the world: a systematic review. Int J Infect Dis 2010; 14: e954-e966.
17. Tortorano AM, Peman J, Bernhardt H. et al. Epidemiology of candidemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Infect Dis 2004; 23: 317-322.
18. Pfaller MA, Moet GJ, Messer SA, Jones RN, Castabheira M. Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY antimicrobial surveillance program, 2008-2009. Antimicrob Agents Chemother 2011; 55: 561-565.
19. Ota KV, McGowan KL. Declining incidence of candidemia in a tertiary inpatient pediatric population. J Clin Microbiol 2012; 50: 1048-1050.
20. Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A, Sheehan D. CLSI subcommittee for antifungal susceptibility testing; wild-type MIC distribution, epidemiological cutoff values and species specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat 2010; 13: 180-195.